Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Shandong Xinhua Pharmaceutical Company Limited Class H ( (HK:0719) ) has issued an update.
Shandong Xinhua Pharmaceutical has obtained regulatory approval from China’s National Medical Products Administration for a supplementary drug application related to its ezetimibe tablets, confirming the change of marketing licence holder to the company. The approval, granted under the country’s drug administration and post-marketing change measures, enables Xinhua Pharmaceutical to assume full marketing authorization responsibilities for the cardiovascular drug.
The change follows a May 2023 agreement under which Beijing Sunshine Nohe Pharmaceutical Research transferred all marketing authorization holder rights for the product, including manufacturing, sales and commercialization, to Xinhua Pharmaceutical. By consolidating control over the ezetimibe business, the company strengthens its product portfolio and commercialization capabilities in the prescription lipid-lowering segment, with potential benefits for its market presence and downstream stakeholders.
The most recent analyst rating on (HK:0719) stock is a Hold with a HK$7.50 price target. To see the full list of analyst forecasts on Shandong Xinhua Pharmaceutical Company Limited Class H stock, see the HK:0719 Stock Forecast page.
More about Shandong Xinhua Pharmaceutical Company Limited Class H
Shandong Xinhua Pharmaceutical Company Limited is a China-based pharmaceutical manufacturer engaged in the research, production and sale of prescription medicines. The company focuses on finished dosage forms such as tablets and operates as a marketing authorization holder in the domestic drug market, supporting its positioning in the broader Chinese healthcare sector.
Average Trading Volume: 1,005,391
Technical Sentiment Signal: Buy
Current Market Cap: HK$10.04B
For a thorough assessment of 0719 stock, go to TipRanks’ Stock Analysis page.